Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 87662 refers to a laboratory test specifically designed for the detection of the Zika virus through the analysis of nucleic acids, which can be either DNA or RNA. This test utilizes an amplified probe technique, which significantly enhances the sensitivity of the assay. The Zika virus is primarily transmitted through mosquito bites and is known to cause a range of symptoms including fever, rash, headache, and joint and muscle pain, typically lasting several days. Most individuals recover from these symptoms; however, the virus poses serious risks during pregnancy, leading to severe birth defects such as microcephaly, as well as potential stillbirth and miscarriage. The amplified probe technique involves a process where the target sequence of the Zika virus's genetic material is exponentially multiplied, resulting in millions of copies. This amplification is commonly achieved through methods such as polymerase chain reaction (PCR) or reverse transcriptase polymerase chain reaction (RT-PCR). Following amplification, the replicated sequences are identified using DNA probes that are labeled with either fluorescent or chemiluminescent markers, ensuring specificity to the target sequence. This method allows for accurate and reliable detection of the Zika virus, which is crucial for diagnosis and subsequent management of affected individuals.
© Copyright 2026 Coding Ahead. All rights reserved.
The CPT® Code 87662 is indicated for the detection of the Zika virus in individuals who may be exhibiting symptoms or have been exposed to the virus. The following conditions warrant the use of this laboratory test:
The procedure for CPT® Code 87662 involves several critical steps to ensure accurate detection of the Zika virus. The following outlines the procedural steps:
Post-procedure care for patients undergoing the Zika virus detection test typically involves monitoring for any immediate reactions to the sample collection. Results from the test are usually available within a specified timeframe, and healthcare providers will discuss the findings with the patient. If the test is positive, further counseling and management options will be provided, especially for pregnant women, to address potential risks to the fetus. It is also important for patients to follow up with their healthcare provider for any additional testing or monitoring that may be necessary based on the results.
| Short Descr | ZIKA VIRUS DNA/RNA AMP PROBE | Medium Descr | IADNA DNA/RNA ZIKA VIRUS AMPLIFIED PROBE TQ | Long Descr | Infectious agent detection by nucleic acid (DNA or RNA); Zika virus, amplified probe technique | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | none | MUE | 2 |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2018-01-01 | Added | Code Added. |
Get instant expert-level medical coding assistance.